ClinicalTrials.gg
RecruitingNCT07216495Updated Oct 7, 2026

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

An interventional study of Exercise in Aerobic Exercise and Early Stage Triple Negative Breast Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Triple Negative Breast Neoplasms by M.D. Anderson Cancer Center — 5 open to participants now, 12 under way, none of them phase 3. Triple Negative Breast Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
15th of 27
33 · median 37
Started
2026
with 1 other
No phase
5 of 29
2 open now
Primary completion
2028-10
later than 10 of 11 live
Registered
28th of 29
by date

Among the 29 studies in Triple Negative Breast Neoplasms by M.D. Anderson Cancer Center, this one is the 15th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 28th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

5 of the 29 studies in Triple Negative Breast Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Triple Negative Breast Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.

Read the detailed description

Primary Objective To evaluate the feasibility of a supervised cardiorespiratory exercise program in patients with clinical stage 2-3 Triple Negative Breast Cancer (TNBC) undergoing neoadjuvant chemotherapy with immune checkpoint inhibitor therapy.

Secondary Objectives To explore the relationship between cardiorespiratory exercise and circulating immune (CD8+ T) cells in the peripheral blood.

03

Conditions studied

  • Aerobic Exercise
  • Early Stage Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. female and male participants 18 years or older and willing to provide
  2. clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 () negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization))
  3. Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device
  4. Eastern Co-Operative Oncology Group () Performance Status 0-1
  5. Planned receipt of chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel)
  6. clearance to participate in the study by the patient's medical oncologist
  7. normal bone marrow function
  8. able to read/complete study forms/assessments and understand instructions in English

Exclusion criteria

Exclusion criteria:

a) Any physical condition which hinders the ability to safely participate in exercise including: uncontrolled or symptomatic cardiac/respiratory disease (e.g. uncontrolled angina, unusual shortness of breath, congestive heart failure, symptomatic peripheral vascular disease), stroke/myocardial infarction in the past year, fragility fracture, recent or planned orthopedic surgery, or any comorbid condition precluding exercise per the treating physician b) receipt of medications known to influence immune function including (>10 mg prednisone equivalent), other immune-suppressive medication, or beta blockers47 c) Any infection or vaccination within the last 4 weeks d) e) Known -positive participants on combination antiretroviral therapy f) concurrent participation in a therapeutic clinical trial or other exercise program g) pregnant h) medically advised to not exercise i) Unable to walk on a motor-driven treadmill for \~30 minutes at study enrollment j) Adults unable to consent k) No external catheters/drains (e.g., nephrostomy tube, foley catheter). A colostomy or Ileostomy is acceptable.

l) Prior or concurrent non-breast . Those with prior cancers treated with curative intent are eligible. Participants with known (or history) of positive, or positive infection

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Acute cardiorespiratory exercise program

    consisting of 4 in-clinic exercise sessions

    Other: Exercise

Interventions

  • OtherExercise

    Cardiorespiratory training via treadmill walking for 30 minutes; participants will be supervised by a trained exercise physiologist.

06

What researchers measure

Primary outcomes

  1. Adherence

    Feasibility will be measured by adherence to both exercise frequency and time (duration/intensity) at the supervised sessions.

    Time frame: Approximately 8 weeks

Secondary outcomes

  1. Circulating immune (CD8+ T) cells in the peripheral blood

    Change of CD8+ T cells in the peripheral blood from baseline (pre-exercise) to post-exercise state

    Time frame: Approximately 8 weeks

Other outcomes

  1. Other blood-based circulating immune cells pre-, during-, and post-exercise

    NK cells, T regulatory (Treg) cells, markers of T cell exhaustion and immunosenescence (CD57, CD45-RA, PD1, KLRG1, CTLA-4)

    Time frame: Approximately 8 weeks

  2. VO2 peak/max

    peak oxygen uptake

    Time frame: Approximately 8 weeks

  3. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (general cancer)

    This is a Patient-Reported Outcome to measure health-related quality of life in patients with cancer. The instrument consists of 30 items comprising five functional scales (physical, role, emotional, cognitive, and social functioning), one global health status/quality of life scale, three multi-item symptom scales (fatigue, pain, nausea/vomiting), and several single-item symptom measures (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).Responses are scored and transfored to a 0-100 scale. Responses are scored and linearly transformed to a 0-100 scale. For functional scales and the global health status/quality of life scale, higher scores indicate better functioning or quality of life. For symptom scales and single-item measures, higher scores indicate greater symptom severity or burden.

    Time frame: Approximately 8 weeks

  4. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BR42 (breast-specific module)

    This is a Patient-Reported Outcome to measure of quality of life patients with breast cancer. The instrument includes multi-item and single-item scales assessing domains such as systemic therapy side effects, breast and arm symptoms, body image, sexual functioning, sexual enjoyment, future perspective, and treatment-related symptoms. Scores are linearly transformed to a 0-100 scale. For functional scales (e.g., body image, sexual functioning, future perspective), higher scores indicate better functioning. For symptom scales/items (e.g., breast symptoms, systemic therapy side effects), higher scores indicate greater symptom burden or severity.

    Time frame: Approximately 8 weeks

  5. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-FA12

    This is a Patient-Reported Outcome of multidimensional fatigue in patients with cancer. The instrument consists of 12 items evaluating physical fatigue, emotional fatigue, and cognitive fatigue, as well as the extent to which fatigue interferes with daily activities and social functioning. Responses are scored and linearly transformed to a 0-100 scale. Higher scores indicate greater fatigue severity and greater interference with functioning.

    Time frame: Approximately 8 weeks

  6. Breast surgical outcome

    Pathologic complete response (pCR) rate

    Time frame: Approximately 6 months

  7. Safety of chemotherapy and ICI therapy

    Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0)

    Time frame: Approximately 8 weeks

  8. Activity Tracker Data from home walking program: heart rate

    heart rate in beats per minute

    Time frame: Approximately 6 months

  9. Activity Tracker Data from home walking program: step counts

    steps per day

    Time frame: Approximately 6 months

  10. Data from home walking program: active/sedentary time

    number of active versus sedentary minutes per day

    Time frame: Approximately 6 months

  11. Godin Leisure Time Physical Activity Questionnaire

    This is a self-administered instrument used to quantify frequency of leisure time physical activity during a typical 7-day period. Participants report the number of times per week they engage in activities lasting ≥15 minutes at three intensity levels: strenuous (vigorous), moderate, and light (mild). A Leisure Score Index (LSI) will be calculated using the formula: (9 × number of strenuous sessions) + (5 × number of moderate sessions) + (3 × number of light sessions). Scores reflect weighted weekly leisure-time physical activity, with higher scores indicating greater self-reported activity levels. There is no absolute maximum score; a score of 0 indicates no reported leisure-time physical activity.

    Time frame: Approximately 8 weeks

  12. Short Physical Performance Battery (SPPB)

    Measure of functional mobility (balance, lower extremity strength, and functional capacity) through assessment of 3 components (balance test, gait speed test, and chair stand test). Each component is scored from 0-4 points, for a total score range of 0-12. Higher scores indicate better functional mobility.

    Time frame: Approximately 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 32 months after the start.

Of 49 interventional studies with no phase under Triple Negative Breast Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 36. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2025
First posted
Oct 14, 2025
StartActual
Feb 23, 2026
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216495
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Feb 23, 2026
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

Salma Foster
Contact
SYFoster@mdanderson.org
713-794-1613
Livia Geoffrey
Contact
LGeoffrey@mdanderson.org
832-728-6175
Jasmine Sukumar, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion